<DOC>
	<DOCNO>NCT02966860</DOCNO>
	<brief_summary>A single-dose study evaluate oral PK oxycodone/apap solution healthy subject fast condition</brief_summary>
	<brief_title>Single-Dose PK Study Oxycodone/Acetaminophen Solution Healthy Subjects</brief_title>
	<detailed_description>An open-label , single-dose , single-center study evaluate oral PK oxycodone/apap solutions healthy subject fast condition</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Acetaminophen , hydrocodone drug combination</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Subjects must adequately inform understands nature risk study must able provide signature date inform consent form ( ICF ) . Subjects must health status `` healthy '' assess investigator , define clinically significant deviation normal medical history , physical examination , clinical laboratory determination . Subjects must males nonpregnant , nonlactating female , 18 55 year age ( inclusive ) time Screening Visit . Subjects must body mass index ( BMI ) ≥ 19.0 ≤ 30.0 kg/m² minimum weight 110 pound females 130 pound male Screening Visit . The BMI calculate use standard formula weight ( kg ) / ( height [ ] ) 2 . Female subject must negative serum pregnancy test Screening Visit checkin study site . All female subject biologically capable child must agree commit use 2 acceptable method birth control , define nonhormonal form contraception , condom diaphragms spermicidal foam 14 day prior checkin study site duration study participation . Unacceptable method birth control include abstinence , hormonecontaining intrauterine device , uterine ablation , hormonal form contraception , rhythm , withdrawal method . Female subject biologically capable child define postmenopausal female subject amenorrheic least 12 consecutive month prior Screening Visit surgically sterile . Male subject reproductive potential must agree use acceptable method contraception duration study ( surgical sterilization [ vasectomy ] condom spermicide ) . Subjects must able communicate effectively study personnel . Subjects must able willing follow protocol requirement study restriction . A subject ineligible study meet follow criterion Screening Visit checkin study site : Subject vulnerable population , define Code Federal Regulations Title 45 , Part 46 , Section 46.111 ( b ) , include limited employee ( temporary , parttime , full time , etc . ) family member research staff conduct study , sponsor , clinical research organization , institutional review board ( IRB ) . Subject history drug allergy , hypersensitivity , intolerance opioids , APAP , naltrexone , opinion investigator , would place subject particular risk compromise safety subject study . Subject positive test result human immunodeficiency virus ( HIV ) , hepatitis B ( surface antigen ) , hepatitis C virus antibody . Subject thyroidstimulating hormone ( TSH ) value outside reference range Screening Visit . Subject donate significant loss whole blood ( 480 mL ) within 30 day , plasma within 14 day , prior Screening Visit plan donate blood plasma enrol study . Subject smoke use nicotinecontaining product 6 month prior Screening Visit . Subject current recent ( within 2 year Screening Visit ) drug alcohol abuse , define Diagnostic Statistical Manual Mental Disorders Fifth Edition , Diagnostic Criteria Drug Alcohol Abuse . Subject current recent ( within 3 month Screening Visit ) gastrointestinal ( GI ) disease ( include , limited , peptic ulcer , diverticulitis , bowel obstruction , adhesion , malabsorption , paralytic ileus , gastritis , diarrhea ) GI surgery could impact absorption study drug ( include , limited , cholecystectomy gastric bypass gastric band surgery ) . Subject major surgery within 3 month prior Screening Visit . Subject history , laboratory evidence , bleed clot disorder condition . Subject unable tolerate venipuncture and/or venous access . Subject medical , psychiatric and/or social reason exclusion , determine investigator . Subject positive test result drug abuse ( minimum : opioids , barbiturate , cannabinoids , benzodiazepine , cocaine , amphetamine ) , cotinine , alcohol Screening Visit checkin study site . Subject use investigational medicinal product ( study drug ) within 30 day prior Screening Visit throughout duration study plan participate another clinical study concurrently enrol study . Subject take prescription drug overthecounter ( OTC ) medication , vitamin , mineral , dietary/herbal supplement ( include grapefruit juice grapefruitcontaining product , St. John 's wort St. John 's wortcontaining product ) within 14 day prior checkin study site throughout duration study . Subject history condition might specifically contraindicate require caution use administration drug study . Subject present history acute illness within 14 day prior checkin study site throughout duration study . Subject electrocardiogram ( ECG ) parameter ( confirm repeat evaluation ) outside follow limit : PR ≥ 210 m , QRS ≥ 120 m , QT ≥ 500 m ; QT interval correct heart rate incorporate Bazett 's formula ( QTcB ) ≥ 450 ms. Subject clinically significant ECG abnormality , assess investigator . Subject oxygen saturation &lt; 95 % .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>